Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
暂无分享,去创建一个
P. Seeburg | R. Sprengel | J. Kuriyan | J. Adelman | J. Maylie | W. Bornmann | T. Schindler | P. Pellicena | W. Miller | B. Clarkson | T. Neelands | W. Kaufmann | D. Pribnow | J. Bissonnette | H. Knaus | J. Jerecic | M. Baetscher | T. Storck | Jasna Jerecic
[1] Matthew B. Wilson,et al. Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective Hck* , 2000, The Journal of Biological Chemistry.
[2] A. Kazlauskas,et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. , 1999, Genes & development.
[3] J. Kuriyan,et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.
[4] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[5] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[6] E. Goldsmith,et al. Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.
[7] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[8] S. Hubbard,et al. Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.
[9] G. Superti-Furga,et al. An intramolecular SH3-domain interaction regulates c-Abl activity , 1998, Nature Genetics.
[10] S. Hubbard. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.
[11] G. Bemis,et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.
[12] S. Hubbard,et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. , 1997, Science.
[13] Jürg Zimmermann,et al. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .
[14] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[15] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[16] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[17] L. Johnson,et al. Active and Inactive Protein Kinases: Structural Basis for Regulation , 1996, Cell.
[18] D. Kassel,et al. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. , 1995, Biochemistry.
[19] Charis Eng,et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.
[20] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[21] S. Hubbard,et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.
[22] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[23] D. Baltimore,et al. N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl. , 1989, The EMBO journal.
[24] J. Wang,et al. Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.